Skip to content

Comparing the effect of Low Level Laser Therapy on low back pain with Naproxen

Comparing the effect of Low Level Laser Therapy on Mechanical LBP(without radiculopathy) with Naproxen

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201711058146N28
Enrollment
40
Registered
2017-11-05
Start date
2011-12-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mechanical LBP(without radiculopathy). Lumbosacral plexus disorders

Interventions

Intervention 1: Intervention group: For a period of one month, the lasers are powered by a 808nm diode laser device with a power supply of 160 mW, and the lumbar, trigger points, thunder points, and s
Treatment - Other
Treatment - Drugs
Intervention group: For a period of one month, the lasers are powered by a 808nm diode laser device with a power supply of 160 mW, and the lumbar, trigger points, thunder points, and some acupuncture
Control group: One month is used in the laser. Naproxen is given at a dose of 1000-250 mg daily for free (ie, if necessary) intake and daily intake is recorded in a table

Sponsors

Vice chancellor for research,Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Being over the age of; A written consent form has been signed; VAS level is between 10-3; According to the expert's diagnosis, the cause of their lower back pain is mechanical and lack of radiculopathy; Their lower back pain is more than three months; Exclusion criteria: Patients requiring emergency surgery:Bladder symptoms such as bladder loss, bladder loss, incontinence, lack of Sense while passing urine, Stomach incontinence , Anesthetizing around the anus ; Pregnancy; Discontinuation of the drug prescribed in / out of the protocol for the administration of the drug; A history of serious gastrointestinal complications (perforation / bleeding) due to the use of various types of NSAIDs; Being / detecting any type of cancer 6 patients with heart problems; Patients who have spinal cord stenosis;Radiculopathy (Pulmonary to subcutaneous pain); Sensory impairment; Muscle weakness; Patients who have taken rococtane over the past 3 months; Patients with asthma, allergic to aspirin or nasal polyps; Patients with severe depression and not being treated; Patients with psychosis;

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
The degree of disability patients. Timepoint: One month after the treatment and the end of the third month. Method of measurement: Ronald-Morris Questionnaire and Oswestry Standard.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Leila Kholoosi

Laser Application Research Center in Medical Science

Lilykh.md2537@yahoo.com+98 21 2274 9221

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026